Tribenoside (Glyvenol) is a vasoprotective drug used to treat hemorrhoids. It has mild anti-inflammatory, analgesic, and wound healing properties. Tribenoside stimulates laminin α5 production and laminin-332 deposition to help repair the basement membrane during the wound healing process. It is a mixture of the α- and β-anomers.
Tribenoside has been shown to induce drug hypersensitivity syndrome in association with CMV reactivation.
References
Lorenc Z, Gökçe Ö (2016). "Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence". Eur Rev Med Pharmacol Sci. 20 (12): 2742–51. PMID 27383331. https://www.europeanreview.org/article/11037 ↩
Jaques R (1977). "The pharmacological activity of tribenoside". Pharmacology. 15 (5): 445–60. doi:10.1159/000136721. PMID 578928. https://www.karger.com/Article/Abstract/136721 ↩
Kikkawa Y, Takaki S, Matsuda Y, Okabe K, Taniguchi M, Oomachi K, Samejima T, Katagiri F, Hozumi K, Nomizu M (2010). "The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells". Biol Pharm Bull. 33 (2): 307–10. doi:10.1248/bpb.33.307. PMID 20118558.{{cite journal}}: CS1 maint: multiple names: authors list (link) https://www.jstage.jst.go.jp/article/bpb/33/2/33_2_307/_article ↩
Hashizume H, Takigawa M (2005). "Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells". Acta Derm. Venereol. 85 (1): 47–50. doi:10.1080/00015550410024094. PMID 15848991. https://doi.org/10.1080%2F00015550410024094 ↩